Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3-Methyladenine is a synthetic small molecule belonging to the class of organic compounds known as purines. It is structurally characterized as a methylated derivative of adenine with a methyl group at the N-3 position. Its primary mechanism of action is inhibition of phosphatidylinositol 3-kinase (PI3K), particularly class III PI3K (Vps34), which leads to suppression of autophagy by blocking autophagosome formation[2][4][9]. This compound is widely used in research as an experimental tool to study autophagy and related cellular processes. In addition to its role in inhibiting autophagy via PI3K inhibition[2][4], it has been shown to modulate other cellular pathways such as stimulating protein kinase A (PKA) activity and increasing lipolysis in adipocytes through cAMP elevation[5]. At higher concentrations or under certain conditions it can induce cytotoxicity and DNA damage independent of AKT/mTOR signaling[7]. It does not have approved therapeutic indications and is primarily used for laboratory research.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3-methyladenine.